Icatibant Injection, Solution
Product Images NDC 24201-207

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Icatibant (NDC 24201-207). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Icatibant 01)

Chemical structure of icatibant, the active ingredient in Icatibant injection, solution 30 mg/3 mL by Hikma Pharmaceuticals USA Inc. The structure shows the molecular configuration of this peptide drug.*

FDA Label Image

Figure 2 (Icatibant 02)

A survival-type line graph comparing the proportion of patients not achieving a 50% reduction in symptoms over time after dosing with Icatibant versus placebo. The x-axis shows time from dose in hours, and the y-axis shows the proportion of patients. Two lines represent Icatibant (solid) and placebo (dashed), illustrating a faster reduction in symptoms with Icatibant over a 60-hour period.*

FDA Label Image

Figure A (Icatibant 03)

An instructional illustration showing components of a prefilled syringe assembly for injection. It identifies the plunger, syringe barrel, and protective cap over the syringe tip on the syringe, as well as the capped needle with needle cap and rigid cap, and an alcohol wipe (not included in the carton). No specific product branding or strength is visible.*

FDA Label Image

Figure B (Icatibant 04)

An instructional diagram showing a hand opening a box containing a syringe with a needle and a capped vial inside. The image illustrates the unboxing or preparation step for subcutaneous injection.*

FDA Label Image

Figure C (Icatibant 05)

An instructional line drawing showing hands preparing an injection by removing a cap from a syringe or vial, associated with Icatibant 30 mg/3mL injection, solution for subcutaneous use, by Hikma Pharmaceuticals USA Inc.*

FDA Label Image

Figure D (Icatibant 06)

An instructional illustration showing how to prepare a subcutaneous injection with a prefilled syringe. The image depicts a hand holding the syringe and another hand placing or removing a small cap or seal, with an arrow indicating the action to be performed.*

FDA Label Image

Figure E (Icatibant 07)

An instructional illustration showing hands twisting a syringe cap or component, indicating a step in the preparation or use of a subcutaneous injection of Icatibant 30 mg/3 mL solution by Hikma Pharmaceuticals USA Inc.*

FDA Label Image

Figure F (Icatibant 08)

An instructional diagram illustrating the recommended subcutaneous injection sites on the abdomen. The image shows two shaded rectangular areas on the left and right side of the lower abdomen, positioned symmetrically around the navel, indicating preferred injection locations for Icatibant solution.*

FDA Label Image

Figure G (Icatibant 09)

Illustration showing a person administering an injection into the abdomen with one hand holding the skin and the other hand injecting. This likely represents subcutaneous injection technique.*

FDA Label Image

Figure H (Icatibant 10)

An instructional illustration showing a hand holding a syringe and another hand holding a vial, demonstrating the process of drawing a solution from the vial into the syringe. The image relates to preparing an injection, typically subcutaneous, such as Icatibant 30 mg/3 mL injection solution by Hikma Pharmaceuticals.*

FDA Label Image

Figure I (Icatibant 11)

An instructional illustration showing a hand holding a syringe used for subcutaneous injection. The image demonstrates the proper grip on the syringe, relevant to the administration of Icatibant injection solution.*

FDA Label Image

Figure J (Icatibant 12)

An instructional line drawing showing a hand holding a syringe for subcutaneous injection in the abdominal area, demonstrating the injection site for Icatibant injection, solution, 30 mg/3 mL by Hikma Pharmaceuticals USA Inc.*

FDA Label Image

Figure K (Icatibant 13)

Instructional illustration showing how to administer a subcutaneous injection using a syringe. It depicts the syringe held at a 45-degree angle for the first injection and at a 90-degree angle for the second injection, with hands positioned on the injection site.*

FDA Label Image

Figure L (Icatibant 14)

An instructional illustration showing a person administering a subcutaneous injection into the abdomen with one hand holding the syringe and the other hand pulling the skin to the side, demonstrating the proper injection technique.*

FDA Label Image

Figure M (Icatibant 15)

An instructional line drawing showing a hand administering a subcutaneous injection with a syringe into the upper arm or shoulder area of the opposite arm, indicating the technique for injecting Icatibant subcutaneously.*

FDA Label Image

Figure N (Icatibant 16)

An instructional illustration showing a hand holding a syringe positioned for subcutaneous injection into the abdomen area, indicating the proper injection site and technique for administering Icatibant injection solution.*

FDA Label Image

Figure O (Icatibant 17)

An instructional illustration showing a hand holding a syringe being inserted into a biohazard sharps disposal container. The container is labeled with biohazard symbols and warnings stating "DO NOT RECYCLE CONTAINS SHARPS." The other hand is holding the container lid, indicating safe disposal of needles or sharps.*

FDA Label Image

1 Pack (Icatibant 18)

Icatibant Injection 30 mg/3 mL (10 mg/mL) single-dose prefilled syringe carton label. The label shows that it is for subcutaneous injection, distributed by Hikma Pharmaceuticals USA Inc., and includes inactive ingredients and storage instructions. The product is manufactured in China, NDC 24201-207-01.*

FDA Label Image

3 Pack (Icatibant 19)

Packaging label for Icatibant Injection 30 mg/3 mL (10 mg/mL) solution for subcutaneous injection by Hikma Pharmaceuticals USA Inc. The carton contains three single-dose, prefilled 3 mL syringes. The label includes dosage strength, usage instructions, distributor information, and storage conditions (2° to 25°C).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.